0000000000728845

AUTHOR

Jan Moritz Middeke

showing 2 related works from this author

Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results…

2018

CD20biologybusiness.industrymedicine.medical_treatmentHematologyImmunotherapyHematopoietic stem cell transplantationmedicine.diseaseOfatumumabTransplantation03 medical and health sciencesLeukemiachemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisImmunologyMonoclonalbiology.proteinMedicineStem cellbusiness030215 immunologyBritish Journal of Haematology
researchProduct

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (…

2020

Introduction The antibody-drug conjugate polatuzumab vedotin (Pola) has recently been approved in combination with bendamustine and rituximab (Pola-BR) for patients with r/r diffuse LBCL (DLBCL). Methods To characterize the efficacy of Pola-BR in a real-world setting, we retrospectively analyzed data from 97 patients with r/r LBCL who were treated with Pola in 24 German centers within the national CUP. Clinical baseline and follow-up (FU) data were collected by chart review and summarized descriptively. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression methods. Fisher's exact test was used to compare categorical factors between gro…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCompassionate UseCell BiologyHematologymedicine.diseaseBiochemistrylanguage.human_languagePolatuzumab vedotinGermanRefractoryInternal medicinemedicinelanguagebusinessB-cell lymphomaReal world dataBlood
researchProduct